Puma Biotechnology
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Articles with Puma Biotechnology
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
3 Takeaways from Puma Biotechnology's 2018 Earnings | The Motley Fool
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting | Business Wire
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology Has a Simple Plan to Get Back to Growth | The Motley Fool
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology to Participate in Panel Discussion at Citi's Biotech Conference
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotechnology Stock News (PBYI) - Public.com
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Inc
